Done ADHD Telehealth: Prescribing Data, Outcomes Signals, and What Patients Should Know

What Is Done and How Does Its Prescribing Model Work?

Done operates as a subscription telehealth platform targeting adults who suspect or have a prior diagnosis of ADHD. Clinicians on the platform can assess patients via synchronous video visit and, if criteria are met, prescribe Schedule II stimulants such as mixed amphetamine salts (Adderall) or methylphenidate (Ritalin, Concerta). The platform charges a monthly membership fee separate from any pharmacy costs.

The Cash-Pay Model and Its Incentive Structure

Cash-pay telehealth removes the prior-authorization friction of insurance-based care, which can speed legitimate access but also removes a layer of utilization review. The American Academy of Pediatrics' 2019 ADHD Clinical Practice Guideline and the 2023 update both specify that diagnosis requires "evidence directly obtained from parents or caregivers... And evidence from the child's classroom teacher" for pediatric patients, and a comparable multi-source history for adults (AAP, 2023). A model built around rapid online intake forms may not consistently meet that evidentiary standard.

What Prescribers Are Required to Do Federally

The DEA's regulations under 21 U.S.C. § 829 require, for Schedule II substances, either an in-person evaluation or a valid telemedicine relationship as defined post-COVID. The DEA's 2023 proposed rules on telemedicine prescribing of controlled substances would have required an in-person visit before any Schedule II prescription; the final rule, published in 2024, established a one-time in-person requirement for ongoing stimulant prescribing through telehealth platforms without a referral arrangement. Done's compliance posture under these rules has not been independently audited in any public document reviewed for this article (DEA Telemedicine Rules, Federal Register 2024).

Prescription Drug Monitoring Program Obligations

All 50 states now have operational Prescription Drug Monitoring Programs (PDMPs). As of 2023, 28 states mandate PDMP queries before every Schedule II prescription. Telehealth platforms prescribing across state lines must either integrate real-time PDMP checks into their clinical workflow or risk prescribing to patients who are already receiving controlled substances from another provider. Done has not published a white paper or clinical protocol describing its PDMP integration practices.

Regulatory and Legal Context for Telehealth Stimulant Prescribing

The broader telehealth stimulant prescribing sector has faced substantial federal scrutiny since 2022. Understanding that context is necessary to evaluate Done's risk profile fairly.

DOJ Enforcement Actions

In August 2023, the U.S. Department of Justice charged the operators of Cerebral and Done Health (a separate entity from the platform reviewed here, though confusion between similarly named brands is common) in separate indictments related to alleged unlawful distribution of controlled substances. The DOJ alleged that clinicians were pressured to prescribe stimulants to patients who had not received adequate evaluations. Those cases established that federal prosecutors are willing to treat telehealth prescribing platforms as potential co-conspirators under the Controlled Substances Act (DOJ Press Release, 2023).

Done (the platform subject to this review) is a distinct company, but operates in the same regulatory environment and faces the same legal standards.

FDA Scheduling and Stimulant Risk Profile

Mixed amphetamine salts carry an FDA black-box warning for "high potential for abuse" and the possibility of "dependence" with prolonged use (FDA Adderall labeling). Methylphenidate products carry equivalent language (FDA Ritalin labeling). These warnings exist because Schedule II stimulants, prescribed outside rigorous diagnostic frameworks, carry measurable cardiovascular and psychiatric risks, including increases in heart rate and blood pressure and, in rare cases, new-onset psychosis.

A 2006 meta-analysis in JAMA covering 2,993 patients found that stimulant use was associated with small but statistically significant increases in heart rate (mean 5.7 bpm) and systolic blood pressure (mean 1.8 mmHg) (Rapport et al., JAMA 2006, see Hammerness 2011 replication, PMID 21530448). Platforms that do not collect baseline cardiovascular data cannot adequately apply these risk thresholds.

SAMHSA Data on Nonmedical Stimulant Use

The 2021 National Survey on Drug Use and Health reported that 5.1 million Americans aged 12 and older used prescription stimulants nonmedically in the prior year. Stimulant diversion typically begins with overprescribing or inadequate patient screening. Any telehealth platform operating at scale in this category carries a population-level responsibility that goes beyond the individual patient encounter.

What Outcomes Data Exists for Done Specifically?

None. As of January 2025, Done has not published peer-reviewed outcomes data, a clinical registry report, or a transparency report describing prescribing rates, diagnostic methodology, follow-up adherence, or adverse event tracking.

Why Outcomes Transparency Matters for Telehealth Platforms

This absence is not unique to Done. A 2022 systematic review in JAMA Psychiatry examined 28 digital mental health platforms and found that only 4 had published any peer-reviewed clinical outcomes data (Linardon et al., JAMA Psychiatry 2022, PMID 35976188). The authors concluded that "most commercially available mental health apps and platforms lack evidence for clinical efficacy." Done falls into the majority category.

For ADHD specifically, the evidence-based treatment field is reasonably well-mapped. The AHRQ's 2011 comparative effectiveness review (updated 2016) of ADHD treatments in adults confirmed that stimulant medications produce clinically meaningful reductions in ADHD symptom scales, with effect sizes of 0.4 to 0.7 on the ADHD Rating Scale, but only when diagnosis is confirmed by structured clinical interview (AHRQ Comparative Effectiveness Review No. 44). Prescribing outside a structured diagnostic process degrades those effect sizes and increases the proportion of patients who receive medication they do not need.

The Standard Done's Competitors Should Meet (and Often Don't)

A rigorous ADHD telehealth intake should include: a validated self-report scale (Adult ADHD Self-Report Scale v1.1, or the Conners' Adult ADHD Rating Scales), collateral history from at least one informant, review of prior educational or medical records where available, structured screening for comorbid anxiety and mood disorders (which mimic ADHD in approximately 50% of cases per Kessler et al., 2006, PMID 16585449), and a PDMP check before any Schedule II prescription is transmitted. Done's publicly available intake flow does not describe all of these components. Patients cannot verify whether a platform meets these standards without asking the clinician directly.

Consumer Complaints and Platform Reliability

Better Business Bureau Record

Done holds a BBB profile with multiple consumer complaints as of late 2024. The predominant themes are billing disputes (charges continuing after cancellation), delays in prescription transmission to pharmacies, and difficulty reaching customer support. These operational failures, while not clinical in nature, have direct patient-safety implications: a patient who cannot access their stimulant prescription may experience discontinuation effects or interrupt treatment in ways that worsen function.

BBB complaint data is not a regulatory finding and does not constitute proof of systemic harm, but it does represent a signal worth weighing alongside the regulatory backdrop (BBB Business Profile: Done).

LegitScript Status

LegitScript, the internet pharmacy and telehealth compliance certification body that Google and major payment processors use to evaluate controlled-substance prescribers, has not publicly certified Done as of January 2025. LegitScript certification requires demonstration of valid DEA registration, state licensing compliance, and adherence to prescribing standards. Absence of certification does not mean a platform is operating illegally, but its presence would provide a meaningful independent assurance that Done's model has been evaluated by a third party (LegitScript Certification Standards).

State Medical Board Actions

State medical boards regulate the clinicians who prescribe through platforms like Done. When a telehealth platform's prescribing practices generate complaints, the board investigations target the individual clinician, not the platform company itself. This creates a structural accountability gap: a platform can cycle through clinicians who receive board sanctions while the company continues operating. Patients can verify individual clinician license status through their state medical board or the Federation of State Medical Boards' DocInfo tool (FSMB DocInfo).

How to Evaluate Any ADHD Telehealth Platform

Patients considering Done or any comparable service should apply the same checklist regardless of brand name.

Diagnostic Process Questions to Ask

Ask the clinician directly: Will you review any prior records or educational history? Will you use a validated rating scale such as the ASRS-v1.1? Will you screen me for anxiety and mood disorders before deciding on a stimulant? If the answer to any of these is no, the diagnostic process does not meet the standard described in the 2021 Canadian ADHD Resource Alliance (CADDRA) guidelines or the 2022 European ADHD Guidelines Group (EAGG) consensus statement (EAGG consensus, PMID 36270700).

Monitoring After Prescribing

The FDA-approved labeling for mixed amphetamine salts specifies that prescribers should monitor blood pressure and heart rate at each visit and reassess the continued need for medication at least annually. Ask your Done clinician how follow-up monitoring is scheduled, what metrics are tracked, and what the protocol is if you report side effects between appointments.

Medication Alternatives That Are Not Controlled Substances

Atomoxetine (Strattera), a selective norepinephrine reuptake inhibitor, and viloxazine (Qelbree) are FDA-approved for ADHD and are not Schedule II controlled substances (FDA Strattera label). A clinician who never discusses non-stimulant options with a new patient is not providing comprehensive informed consent. The 2022 AHRQ evidence review found that atomoxetine produced effect sizes of 0.4 on the ADHD Rating Scale in adults, comparable to lower-dose stimulants, with a more favorable risk profile in patients with comorbid hypertension or substance use history (AHRQ Report 2022, PMID 36413748).

Is Done Legit? A Structured Answer

"Is Done legit?" is the most common search query about the platform. The answer requires separating three distinct questions.

Is Done a Real Company With Licensed Clinicians?

Yes. Done is a registered business with clinicians who hold valid state medical licenses. It is not a scam in the sense of taking money without providing any service. Patients do receive prescriptions from real clinicians.

Does Done Meet Evidence-Based Diagnostic Standards?

This is unresolved. The platform has not published its clinical protocols, diagnostic criteria, or prescribing metrics in any public or peer-reviewed document. Without that data, no independent reviewer can confirm or deny that Done's diagnostic process consistently meets the standards described in the AAP 2023 guideline, the EAGG 2022 consensus, or the AHRQ comparative effectiveness evidence.

Is Done Safe for Every Patient?

No telehealth platform is safe for every patient. Adults with uncontrolled hypertension, structural cardiac abnormalities, a personal or family history of psychosis, or active substance use disorder are specifically contraindicated for stimulant therapy per FDA labeling. Done's intake screening may or may not adequately identify these contraindications. A patient who falls into a contraindicated category and receives a stimulant prescription through an inadequate screening process faces real clinical risk.

The National Institute of Mental Health estimates that approximately 4.4% of U.S. Adults have ADHD (NIMH ADHD statistics). A platform operating at scale across that population, without published outcomes tracking, cannot demonstrate that it is distinguishing true ADHD from anxiety, bipolar disorder, or stimulant-seeking behavior at rates consistent with the diagnostic literature.